Latest Breaking News On - Johannes de munter - Page 1 : comparemela.com

Neuroplast successfully completes patient inclusion of Phase II clinical trial for Traumatic Spinal Cord Injury

16 patients have been enrolled in a multicenter international, randomized, placebo-controlled, double-blinded Phase II clinical trial Goal: to determine the.

United statesNoord hollandClaus andersenAntonio olivieroErik woltersNetherlands enterprise agencyBrightlands agrifood fundDutch ministry of economic affairsTraumatic spinal cord injuryHospital nacional de paraplPrincipal investigators antonio olivieroHospital paraplProfessor fin biering sPhd claus andersenPrincipal investigatorJohannes de munter

Neuroplast Successfully Completes Patient Inclusion Of Phase Ii Clinical Trial For Traumatic Spinal Cord Injury

Neuroplast Successfully Completes Patient Inclusion Of Phase Ii Clinical Trial For Traumatic Spinal Cord Injury
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Noord hollandErik woltersAntonio olivieroBrightlands agrifood fundDutch ministry of economic affairsNetherlands enterprise agencyTraumatic spinal cord injuryHospital nacional de paraplePrincipal investigators antonio olivieroHospital parapleProfessor fin biering sPhd clandersenPrincipal investigatorJohannes de munterLumana investBrightlands venture partners

Neuroplast receives medicinal product designation for Neuro-Cells

Designation paves way for wider applications for several neurodegenerative diseases - News - PharmaTimes

European unionEuropean medicines agencyJohannes de munterEuro cells

Neuroplast receives second orphan medicinal product designation for Neuro-Cells®, paving the way for application to both chronic and trauma-induced neurodegenerative diseases

Fast-track status is granted for frontotemporal dementia, next to the existing designation for traumatic spinal cord injury An orphan medicinal product.

Noord hollandErik woltersBrightlands agrifood fundCommittee for orphan medicinal productsEuropean unionNetherlands enterprise agencyEuropean medicines agencyDutch ministry of economic affairsFrontotemporal dementiaTraumatic spinal cord injuryTraumatic brainAdvanced therapy medicinal productOrphan medicinal productsJohannes de munterLumana investBrightlands venture partners

Neuroplast receives second orphan medicinal product designation for Neuro-Cells, paving the way for application to both chronic and trauma-induced neurodegenerative diseases

Fast-track status is granted for frontotemporal dementia, next to the existing designation for traumatic spinal cord injury An orphan medicinal product designation or orphan disease designation

Noord hollandKostenloser wertpapierhandelErik woltersBrightlands agrifood fundCommittee for orphan medicinal productsEuropean unionNetherlands enterprise agencyEuropean medicines agencyDutch ministry of economic affairsFrontotemporal dementiaTraumatic spinal cord injuryTraumatic brainAdvanced therapy medicinal productOrphan medicinal productsJohannes de munterLumana invest